Published on August 1, 2012 at 5:02 AM
MDxHealth
SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that
develops and commercializes epigenetic tests to support cancer
treatment, today announced that the company's Irvine, California, CLIA
laboratory has received College of American Pathology (CAP)
accreditation. CAP accreditation is an internationally recognized
program established to improve patient safety by ensuring laboratories
achieve the highest standards of excellence and exceed regulatory
requirements. The first product offered through the Irvine laboratory is
the company's recently launched ConfirmMDx™ for Prostate Cancer test,
which provides urologists with a DNA-based epigenetic assay to help
distinguish patients who have a true-negative prostate biopsy from those
who may have occult cancer.
"CAP
accreditation is the gold standard for quality, and MDxHealth is
committed to delivering high quality clinical diagnostic and
pharmaceutical laboratory services that surpass regulatory
requirements," said Dr. Jan Groen, President and CEO of MDxHealth. "Our
CLIA certified state-of-the-art facility is now fully accredited and
licensed. Each day as our volumes for prostate cancer samples increases,
quality and accuracy remain our priority."
Source: College of American Pathologists